---
title: "Avacta Group PLC (AIM:AVCT) Avacta Therapeutics Division Science Day"
publisher: "Share Talk"
author: "sharetalk"
published: "2023-02-23T07:43:50+00:00"
modified: "2023-02-23T07:43:50+00:00"
date: 2023-02-23
canonical: "https://www.share-talk.com/avacta-group-plc-aimavct-avacta-therapeutics-division-science-day/"
category: "Healthcare"
categories: ["Healthcare"]
tags: ["Abingdon Health", "AffyXell Therapeutics", "antigen", "Avacta Group", "AVCT", "Biotherapeutics", "Chris Yates", "clinical", "COVID-19", "Cytiva", "Daewoong Pharmaceutical", "diagnostic", "Doncaster", "Europe", "LG Chem Life Sciences", "Pharma", "radiopharmaceuticals", "saliva test", "SARS-COV-2", "Sengho Jeon", "Share Talk", "South Korea", "therapeutic", "UK", "validation", "York"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Avacta Group PLC (AIM:AVCT) Avacta Therapeutics Division Science Day

**Published:** February 23, 2023
**Author:** sharetalk
**Categories:** Healthcare
**Tags:** Abingdon Health, AffyXell Therapeutics, antigen, Avacta Group, AVCT, Biotherapeutics, Chris Yates, clinical, COVID-19, Cytiva, Daewoong Pharmaceutical, diagnostic, Doncaster, Europe, LG Chem Life Sciences, Pharma, radiopharmaceuticals, saliva test, SARS-COV-2, Sengho Jeon, Share Talk, South Korea, therapeutic, UK, validation, York
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**Avacta Group plc (AIM: AVCT),** a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is today holding a Science Day, focused on its Therapeutics Division, for institutional investors and analysts as stated in the announcement on the 19 December 2022.

No material new information will be disclosed as part of this meeting.

The event will include a detailed review of the ongoing ALS-6000-101 Phase 1a clinical trial of AVA6000, Avacta’s lead pre|CISION™ tumour targeted form of the chemotherapy drug Doxorubicin, in soft tissue sarcoma, as well as an update on preclinical programmes.

There will also be presentations from two outstanding key opinion leaders in the field of oncology, Professor Krishna Komanduri Chief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, University of California San Francisco, USA and Dr William Tap Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA

A copy of the presentations given at the Science Day will be made available on the Group’s website, along with a full recording of the day, within 24 hours of the end of the meeting.

-Ends-

For further information from Avacta Group plc, please contact:

**Avacta Group plc**

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director

Tel: +44 (0) 1904 21 7070

[www.avacta.com](http://www.avacta.com)

---

**Original URL:** https://www.share-talk.com/avacta-group-plc-aimavct-avacta-therapeutics-division-science-day/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*